SEC Form 4 · accession 0001179110-16-033001
Celldex Therapeutics, Inc. · CLDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Theresa LaVallee
Officer — SVP, Reg.& Precision Medicine
Period of report
Dec 14, 2016
Accepted (ET)
Dec 15, 2016 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000744218
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1,F2 | $3.72 | Dec 14, 2016 | A | 75,000 | A | — | Dec 14, 2026 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.
- F225% of the total amount of shares subject to the Option vests on December 14, 2017 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters, beginning March 14, 2018.